Find Type 2 Diabetes (T2D) Clinical Trials Near You
Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• T2D
• Males and females
• Older than 18 years of age
• Willingness to participate in the study and provide written consent form
• Consent to having peripheral blood withdrawals and urine collection for the study requirement.
Locations
Other Locations
Qatar
Hamad Medical Corporation
RECRUITING
Doha
Time Frame
Start Date:2020-11-17
Estimated Completion Date:2026-12-31
Participants
Target number of participants:90
Treatments
Groupe 1: T2D and no established cardiovascular complications
* HbA1C level ≥ 6.5% and a fasting glucose level ≥126 mg/dl (7.0 mmol/l)~* No concomitant cardiovascular complications (coronary artery disease, stroke, nephropathy, retinopathy, peripheral arterial disease) per the history, medical records and biochemistry.
Groupe 2: T2D and established coronary artery disease
* The presence of coronary artery disease (CAD) confirmed by coronary angiogram prior to the inclusion.~* Patients with concomitant microvascular complications of diabetes will be excluded (nephropathy, retinopathy).
Groupe 3: Control, no T2D
* Fasting glycemia \<100 mg/dl and HbA1C \<5.7%~* Absence of a concomitant cardiovascular disease (CAD, stroke, PAD, neuropathy)